"
Team:SupBiotech-Paris
From 2009.igem.org
(Difference between revisions)
Enguerrand (Talk | contribs) |
|||
| Line 12: | Line 12: | ||
Our project is a vectorization system, we chose mycobacterium, a | Our project is a vectorization system, we chose mycobacterium, a | ||
microorganism with high tropism for specific tissues, and a synthetic | microorganism with high tropism for specific tissues, and a synthetic | ||
| - | Lambda phage able to infect eukaryotic cells.First, to target tissue, we use mycobacterium, and then to target the | + | Lambda phage able to infect eukaryotic cells. First, to target tissue, we use mycobacterium, and then to target the |
cell population, we use the synthetic lambda phage. | cell population, we use the synthetic lambda phage. | ||
</p> | </p> | ||
Revision as of 10:14, 19 August 2009
Project
Introduction Current therapies Gene therapies DVS Concept Tissue Vector Cell Vector Therapeutic plasmid Conclusion Implementation Tissue targeting Antitumor action Treatment modeling Conclusion
Ressources
BioBricks Material & Method Bibliography
Ethics & Safety
Welcome Foreigner,
Our project is a vectorization system, we chose mycobacterium, a microorganism with high tropism for specific tissues, and a synthetic Lambda phage able to infect eukaryotic cells. First, to target tissue, we use mycobacterium, and then to target the cell population, we use the synthetic lambda phage.
See you guys!
